๐ฌDeep Research
VKTX โ Viking Therapeutics ยท catalysts, narrative & risks
Viking Therapeutics (VKTX) โ Point-in-Time Research Brief (as of 2026-11-11)
Overview
Viking Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, focused on metabolic and endocrine disorders with an obesity-centric pipeline [1], [2]. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being developed in both subcutaneous and oral formulations [1], [2], [20]. It trades on the Nasdaq and is categorized among biotech names [14].
Recent Catalysts (roughly AugโNov 2026)
AI-assisted research from the K3vl4r desk โ not personalized investment advice. More research โ